Regeneron Pharmaceuticals, Inc. (REGN) Stock Competitors & Peer Comparison
See (REGN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| REGN | $654.27 | +4.73% | 67.4B | 14.34 | $45.63 | +0.56% |
| VRTX | $528.04 | +6.03% | 134B | 28.06 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $939.68 | +3.32% | 58.2B | 84.81 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $312.78 | +3.68% | 41.8B | 56.36 | $5.55 | N/A |
| RVMDW | $9.55 | +1.70% | 40.5B | -2.30 | -$4.15 | N/A |
| RVMD | $189.24 | +0.92% | 40.2B | -26.77 | -$7.07 | N/A |
| ONC | $297.65 | +2.38% | 31.8B | 66.59 | $4.47 | N/A |
| MRNA | $79.76 | +10.01% | 31.6B | -9.79 | -$8.15 | N/A |
Stock Comparison
REGN vs VRTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, VRTX has a market cap of 134B. Regarding current trading prices, REGN is priced at $654.27, while VRTX trades at $528.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas VRTX's P/E ratio is 28.06. In terms of profitability, REGN's ROE is +0.14%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, REGN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check VRTX's competition here
REGN vs VRNA Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, REGN is priced at $654.27, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas VRNA's P/E ratio is -102.80. In terms of profitability, REGN's ROE is +0.14%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, REGN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check VRNA's competition here
REGN vs ARGX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ARGX has a market cap of 58.2B. Regarding current trading prices, REGN is priced at $654.27, while ARGX trades at $939.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ARGX's P/E ratio is 84.81. In terms of profitability, REGN's ROE is +0.14%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, REGN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ARGX's competition here
REGN vs SGEN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, REGN is priced at $654.27, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas SGEN's P/E ratio is -57.19. In terms of profitability, REGN's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, REGN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check SGEN's competition here
REGN vs ALNY Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ALNY has a market cap of 41.8B. Regarding current trading prices, REGN is priced at $654.27, while ALNY trades at $312.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ALNY's P/E ratio is 56.36. In terms of profitability, REGN's ROE is +0.14%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, REGN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check ALNY's competition here
REGN vs RVMDW Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RVMDW has a market cap of 40.5B. Regarding current trading prices, REGN is priced at $654.27, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RVMDW's P/E ratio is -2.30. In terms of profitability, REGN's ROE is +0.14%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, REGN is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check RVMDW's competition here
REGN vs RVMD Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, REGN is priced at $654.27, while RVMD trades at $189.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RVMD's P/E ratio is -26.77. In terms of profitability, REGN's ROE is +0.14%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, REGN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RVMD's competition here
REGN vs ONC Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ONC has a market cap of 31.8B. Regarding current trading prices, REGN is priced at $654.27, while ONC trades at $297.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ONC's P/E ratio is 66.59. In terms of profitability, REGN's ROE is +0.14%, compared to ONC's ROE of +0.12%. Regarding short-term risk, REGN is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ONC's competition here
REGN vs MRNA Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MRNA has a market cap of 31.6B. Regarding current trading prices, REGN is priced at $654.27, while MRNA trades at $79.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MRNA's P/E ratio is -9.79. In terms of profitability, REGN's ROE is +0.14%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, REGN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check MRNA's competition here
REGN vs ROIV Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ROIV has a market cap of 25.3B. Regarding current trading prices, REGN is priced at $654.27, while ROIV trades at $35.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ROIV's P/E ratio is -38.98. In terms of profitability, REGN's ROE is +0.14%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, REGN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ROIV's competition here
REGN vs BNTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, REGN is priced at $654.27, while BNTX trades at $97.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BNTX's P/E ratio is -21.11. In terms of profitability, REGN's ROE is +0.14%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, REGN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BNTX's competition here
REGN vs INSM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, INSM has a market cap of 24.2B. Regarding current trading prices, REGN is priced at $654.27, while INSM trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas INSM's P/E ratio is -19.41. In terms of profitability, REGN's ROE is +0.14%, compared to INSM's ROE of -1.30%. Regarding short-term risk, REGN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check INSM's competition here
REGN vs UTHR Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, UTHR has a market cap of 23.6B. Regarding current trading prices, REGN is priced at $654.27, while UTHR trades at $555.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas UTHR's P/E ratio is 20.52. In terms of profitability, REGN's ROE is +0.14%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, REGN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check UTHR's competition here
REGN vs INCY Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, INCY has a market cap of 23.3B. Regarding current trading prices, REGN is priced at $654.27, while INCY trades at $116.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas INCY's P/E ratio is 15.71. In terms of profitability, REGN's ROE is +0.14%, compared to INCY's ROE of +0.29%. Regarding short-term risk, REGN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check INCY's competition here
REGN vs BGNE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, REGN is priced at $654.27, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BGNE's P/E ratio is -22.55. In terms of profitability, REGN's ROE is +0.14%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, REGN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BGNE's competition here
REGN vs DNA-WT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, REGN is priced at $654.27, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, REGN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check DNA-WT's competition here
REGN vs NBIX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, NBIX has a market cap of 17.5B. Regarding current trading prices, REGN is priced at $654.27, while NBIX trades at $174.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas NBIX's P/E ratio is 25.18. In terms of profitability, REGN's ROE is +0.14%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, REGN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check NBIX's competition here
REGN vs GMAB Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, GMAB has a market cap of 17.5B. Regarding current trading prices, REGN is priced at $654.27, while GMAB trades at $28.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas GMAB's P/E ratio is 20.51. In terms of profitability, REGN's ROE is +0.14%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, REGN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check GMAB's competition here
REGN vs ASND Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ASND has a market cap of 17B. Regarding current trading prices, REGN is priced at $654.27, while ASND trades at $274.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ASND's P/E ratio is -113.43. In terms of profitability, REGN's ROE is +0.14%, compared to ASND's ROE of -56.42%. Regarding short-term risk, REGN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ASND's competition here
REGN vs JAZZ Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, JAZZ has a market cap of 15.3B. Regarding current trading prices, REGN is priced at $654.27, while JAZZ trades at $243.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas JAZZ's P/E ratio is 18.93. In terms of profitability, REGN's ROE is +0.14%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, REGN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check JAZZ's competition here
REGN vs BBIO Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, REGN is priced at $654.27, while BBIO trades at $77.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BBIO's P/E ratio is -20.64. In terms of profitability, REGN's ROE is +0.14%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, REGN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BBIO's competition here
REGN vs EXEL Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, REGN is priced at $654.27, while EXEL trades at $55.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas EXEL's P/E ratio is 16.72. In terms of profitability, REGN's ROE is +0.14%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check EXEL's competition here
REGN vs IONS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, IONS has a market cap of 13.5B. Regarding current trading prices, REGN is priced at $654.27, while IONS trades at $81.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas IONS's P/E ratio is -47.56. In terms of profitability, REGN's ROE is +0.14%, compared to IONS's ROE of -0.59%. Regarding short-term risk, REGN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check IONS's competition here
REGN vs KRTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, REGN is priced at $654.27, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas KRTX's P/E ratio is -28.09. In terms of profitability, REGN's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, REGN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check KRTX's competition here
REGN vs AXSM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, AXSM has a market cap of 12.6B. Regarding current trading prices, REGN is priced at $654.27, while AXSM trades at $244.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas AXSM's P/E ratio is -63.79. In terms of profitability, REGN's ROE is +0.14%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, REGN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check AXSM's competition here
REGN vs MDGL Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, REGN is priced at $654.27, while MDGL trades at $528.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MDGL's P/E ratio is -41.26. In terms of profitability, REGN's ROE is +0.14%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, REGN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check MDGL's competition here
REGN vs SMMT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, REGN is priced at $654.27, while SMMT trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas SMMT's P/E ratio is -9.64. In terms of profitability, REGN's ROE is +0.14%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, REGN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check SMMT's competition here
REGN vs ARWR Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ARWR has a market cap of 11.8B. Regarding current trading prices, REGN is priced at $654.27, while ARWR trades at $83.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ARWR's P/E ratio is -39.07. In terms of profitability, REGN's ROE is +0.14%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, REGN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check ARWR's competition here
REGN vs BMRN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, REGN is priced at $654.27, while BMRN trades at $58.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BMRN's P/E ratio is 28.36. In terms of profitability, REGN's ROE is +0.14%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, REGN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BMRN's competition here
REGN vs RNAM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $654.27, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RNAM's P/E ratio is -17.39. In terms of profitability, REGN's ROE is +0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, REGN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RNAM's competition here
REGN vs TECH Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, REGN is priced at $654.27, while TECH trades at $70.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TECH's P/E ratio is 36.51. In terms of profitability, REGN's ROE is +0.14%, compared to TECH's ROE of +0.05%. Regarding short-term risk, REGN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check TECH's competition here
REGN vs KRYS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, KRYS has a market cap of 11.1B. Regarding current trading prices, REGN is priced at $654.27, while KRYS trades at $375.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas KRYS's P/E ratio is 50.14. In terms of profitability, REGN's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, REGN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check KRYS's competition here
REGN vs CYTK Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CYTK has a market cap of 10.8B. Regarding current trading prices, REGN is priced at $654.27, while CYTK trades at $86.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CYTK's P/E ratio is -14.84. In terms of profitability, REGN's ROE is +0.14%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, REGN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CYTK's competition here
REGN vs CORT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CORT has a market cap of 9.7B. Regarding current trading prices, REGN is priced at $654.27, while CORT trades at $90.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CORT's P/E ratio is 257.74. In terms of profitability, REGN's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, REGN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CORT's competition here
REGN vs IBRX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, IBRX has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $654.27, while IBRX trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas IBRX's P/E ratio is -28.75. In terms of profitability, REGN's ROE is +0.14%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, REGN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check IBRX's competition here
REGN vs RXDX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $654.27, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RXDX's P/E ratio is -56.47. In terms of profitability, REGN's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RXDX's competition here
REGN vs ABVX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ABVX has a market cap of 9.5B. Regarding current trading prices, REGN is priced at $654.27, while ABVX trades at $144.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ABVX's P/E ratio is -75.66. In terms of profitability, REGN's ROE is +0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, REGN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check ABVX's competition here
REGN vs HALO Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, HALO has a market cap of 9.4B. Regarding current trading prices, REGN is priced at $654.27, while HALO trades at $79.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas HALO's P/E ratio is 17.20. In terms of profitability, REGN's ROE is +0.14%, compared to HALO's ROE of +1.26%. Regarding short-term risk, REGN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check HALO's competition here
REGN vs KYMR Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, KYMR has a market cap of 9.3B. Regarding current trading prices, REGN is priced at $654.27, while KYMR trades at $113.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas KYMR's P/E ratio is -32.16. In terms of profitability, REGN's ROE is +0.14%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, REGN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check KYMR's competition here
REGN vs NUVL Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $654.27, while NUVL trades at $123.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas NUVL's P/E ratio is -21.75. In terms of profitability, REGN's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, REGN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check NUVL's competition here
REGN vs ALKS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ALKS has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $654.27, while ALKS trades at $54.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ALKS's P/E ratio is 57.45. In terms of profitability, REGN's ROE is +0.14%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, REGN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check ALKS's competition here
REGN vs IMGN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, REGN is priced at $654.27, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas IMGN's P/E ratio is -111.55. In terms of profitability, REGN's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, REGN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check IMGN's competition here
REGN vs PTGX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, REGN is priced at $654.27, while PTGX trades at $131.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas PTGX's P/E ratio is -72.78. In terms of profitability, REGN's ROE is +0.14%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, REGN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check PTGX's competition here
REGN vs PCVX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $654.27, while PCVX trades at $58.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas PCVX's P/E ratio is -8.49. In terms of profitability, REGN's ROE is +0.14%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, REGN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check PCVX's competition here
REGN vs BPMC Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $654.27, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BPMC's P/E ratio is -51.58. In terms of profitability, REGN's ROE is +0.14%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, REGN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BPMC's competition here
REGN vs APGE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $654.27, while APGE trades at $132.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas APGE's P/E ratio is -30.70. In terms of profitability, REGN's ROE is +0.14%, compared to APGE's ROE of -0.33%. Regarding short-term risk, REGN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check APGE's competition here
REGN vs CERE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $654.27, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CERE's P/E ratio is -16.47. In terms of profitability, REGN's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, REGN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CERE's competition here
REGN vs TGTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $654.27, while TGTX trades at $53.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TGTX's P/E ratio is 18.32. In terms of profitability, REGN's ROE is +0.14%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, REGN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check TGTX's competition here
REGN vs IMVT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, REGN is priced at $654.27, while IMVT trades at $38.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas IMVT's P/E ratio is -14.53. In terms of profitability, REGN's ROE is +0.14%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, REGN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check IMVT's competition here
REGN vs RYTM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, REGN is priced at $654.27, while RYTM trades at $114.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RYTM's P/E ratio is -36.48. In terms of profitability, REGN's ROE is +0.14%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, REGN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RYTM's competition here
REGN vs MTSR Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, REGN is priced at $654.27, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MTSR's P/E ratio is -23.58. In terms of profitability, REGN's ROE is +0.14%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, REGN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check MTSR's competition here
REGN vs LQDA Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, LQDA has a market cap of 7B. Regarding current trading prices, REGN is priced at $654.27, while LQDA trades at $78.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas LQDA's P/E ratio is 563.79. In terms of profitability, REGN's ROE is +0.14%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, REGN is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check LQDA's competition here
REGN vs PTCT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, PTCT has a market cap of 6.9B. Regarding current trading prices, REGN is priced at $654.27, while PTCT trades at $83.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas PTCT's P/E ratio is -35.76. In terms of profitability, REGN's ROE is +0.14%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, REGN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check PTCT's competition here
REGN vs MRUS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, REGN is priced at $654.27, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MRUS's P/E ratio is -17.05. In terms of profitability, REGN's ROE is +0.14%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, REGN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check MRUS's competition here
REGN vs PRAX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $654.27, while PRAX trades at $318.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas PRAX's P/E ratio is -23.82. In terms of profitability, REGN's ROE is +0.14%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, REGN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check PRAX's competition here
REGN vs ACLX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $654.27, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ACLX's P/E ratio is -28.27. In terms of profitability, REGN's ROE is +0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, REGN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ACLX's competition here
REGN vs COGT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $654.27, while COGT trades at $38.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas COGT's P/E ratio is -18.34. In terms of profitability, REGN's ROE is +0.14%, compared to COGT's ROE of -0.83%. Regarding short-term risk, REGN is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check COGT's competition here
REGN vs SRRK Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $654.27, while SRRK trades at $54.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas SRRK's P/E ratio is -15.29. In terms of profitability, REGN's ROE is +0.14%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, REGN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check SRRK's competition here
REGN vs RETA Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $654.27, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RETA's P/E ratio is -66.29. In terms of profitability, REGN's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, REGN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RETA's competition here
REGN vs LGND Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, REGN is priced at $654.27, while LGND trades at $319.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas LGND's P/E ratio is 38.32. In terms of profitability, REGN's ROE is +0.14%, compared to LGND's ROE of +0.16%. Regarding short-term risk, REGN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check LGND's competition here
REGN vs MIRM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MIRM has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $654.27, while MIRM trades at $125.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MIRM's P/E ratio is -9.23. In terms of profitability, REGN's ROE is +0.14%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, REGN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check MIRM's competition here
REGN vs CNTA Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $654.27, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CNTA's P/E ratio is -22.63. In terms of profitability, REGN's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, REGN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CNTA's competition here
REGN vs CGON Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CGON has a market cap of 6.2B. Regarding current trading prices, REGN is priced at $654.27, while CGON trades at $70.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CGON's P/E ratio is -30.20. In terms of profitability, REGN's ROE is +0.14%, compared to CGON's ROE of -0.23%. Regarding short-term risk, REGN is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CGON's competition here
REGN vs BLTE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, REGN is priced at $654.27, while BLTE trades at $146.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BLTE's P/E ratio is -78.41. In terms of profitability, REGN's ROE is +0.14%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, REGN is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check BLTE's competition here
REGN vs CRSP Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, REGN is priced at $654.27, while CRSP trades at $60.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CRSP's P/E ratio is -11.76. In terms of profitability, REGN's ROE is +0.14%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, REGN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check CRSP's competition here
REGN vs ERAS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, REGN is priced at $654.27, while ERAS trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ERAS's P/E ratio is -41.98. In terms of profitability, REGN's ROE is +0.14%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, REGN is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check ERAS's competition here
REGN vs CDTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $654.27, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CDTX's P/E ratio is -19.77. In terms of profitability, REGN's ROE is +0.14%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, REGN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CDTX's competition here
REGN vs LEGN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, LEGN has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $654.27, while LEGN trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas LEGN's P/E ratio is -43.99. In terms of profitability, REGN's ROE is +0.14%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, REGN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check LEGN's competition here
REGN vs ABCM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $654.27, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, REGN's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, REGN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ABCM's competition here
REGN vs ISEE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $654.27, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ISEE's P/E ratio is -22.44. In terms of profitability, REGN's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, REGN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ISEE's competition here
REGN vs MANE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MANE has a market cap of 5.4B. Regarding current trading prices, REGN is priced at $654.27, while MANE trades at $129.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MANE's P/E ratio is -41.28. In terms of profitability, REGN's ROE is +0.14%, compared to MANE's ROE of -0.84%. Regarding short-term risk, REGN is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check MANE's competition here
REGN vs TVTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $654.27, while TVTX trades at $56.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TVTX's P/E ratio is -258.66. In terms of profitability, REGN's ROE is +0.14%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, REGN is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check TVTX's competition here
REGN vs CELC Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $654.27, while CELC trades at $107.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CELC's P/E ratio is -27.68. In terms of profitability, REGN's ROE is +0.14%, compared to CELC's ROE of -2.45%. Regarding short-term risk, REGN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check CELC's competition here
REGN vs APLS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $654.27, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas APLS's P/E ratio is 38.35. In terms of profitability, REGN's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check APLS's competition here
REGN vs SYRE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, SYRE has a market cap of 5.2B. Regarding current trading prices, REGN is priced at $654.27, while SYRE trades at $86.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas SYRE's P/E ratio is -41.65. In terms of profitability, REGN's ROE is +0.14%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, REGN is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check SYRE's competition here
REGN vs CAI Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, REGN is priced at $654.27, while CAI trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CAI's P/E ratio is -100.66. In terms of profitability, REGN's ROE is +0.14%, compared to CAI's ROE of +0.06%. Regarding short-term risk, REGN is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check CAI's competition here
REGN vs DFTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $654.27, while DFTX trades at $44.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas DFTX's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, REGN is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check DFTX's competition here
REGN vs XENE Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, XENE has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $654.27, while XENE trades at $60.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas XENE's P/E ratio is -12.97. In terms of profitability, REGN's ROE is +0.14%, compared to XENE's ROE of -0.49%. Regarding short-term risk, REGN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check XENE's competition here
REGN vs TERN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $654.27, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TERN's P/E ratio is -51.41. In terms of profitability, REGN's ROE is +0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, REGN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check TERN's competition here
REGN vs FOLD Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $654.27, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas FOLD's P/E ratio is -161.00. In terms of profitability, REGN's ROE is +0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, REGN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check FOLD's competition here
REGN vs AKRO Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $654.27, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas AKRO's P/E ratio is -14.57. In terms of profitability, REGN's ROE is +0.14%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check AKRO's competition here
REGN vs ALPN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $654.27, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ALPN's P/E ratio is -101.52. In terms of profitability, REGN's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, REGN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ALPN's competition here
REGN vs CRNX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CRNX has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $654.27, while CRNX trades at $42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CRNX's P/E ratio is -8.23. In terms of profitability, REGN's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, REGN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check CRNX's competition here
REGN vs ACAD Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, REGN is priced at $654.27, while ACAD trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas ACAD's P/E ratio is 12.73. In terms of profitability, REGN's ROE is +0.14%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, REGN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check ACAD's competition here
REGN vs VKTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $654.27, while VKTX trades at $37.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas VKTX's P/E ratio is -9.04. In terms of profitability, REGN's ROE is +0.14%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, REGN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check VKTX's competition here
REGN vs EWTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $654.27, while EWTX trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas EWTX's P/E ratio is -23.83. In terms of profitability, REGN's ROE is +0.14%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, REGN is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check EWTX's competition here
REGN vs NAMSW Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $654.27, while NAMSW trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas NAMSW's P/E ratio is -12.96. In terms of profitability, REGN's ROE is +0.14%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, REGN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check NAMSW's competition here
REGN vs OPT Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $654.27, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas OPT's P/E ratio is -1.52. In terms of profitability, REGN's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, REGN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check OPT's competition here
REGN vs MRTX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $654.27, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas MRTX's P/E ratio is -4.82. In terms of profitability, REGN's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, REGN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check MRTX's competition here
REGN vs DNLI Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $654.27, while DNLI trades at $25.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas DNLI's P/E ratio is -8.97. In terms of profitability, REGN's ROE is +0.14%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, REGN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check DNLI's competition here
REGN vs NAMS Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $654.27, while NAMS trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas NAMS's P/E ratio is -21.91. In terms of profitability, REGN's ROE is +0.14%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check NAMS's competition here
REGN vs TLX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, REGN is priced at $654.27, while TLX trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TLX's P/E ratio is -646.16. In terms of profitability, REGN's ROE is +0.14%, compared to TLX's ROE of -0.02%. Regarding short-term risk, REGN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check TLX's competition here
REGN vs DNTH Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, DNTH has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $654.27, while DNTH trades at $94.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas DNTH's P/E ratio is -22.84. In terms of profitability, REGN's ROE is +0.14%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, REGN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check DNTH's competition here
REGN vs CPRX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $654.27, while CPRX trades at $31.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CPRX's P/E ratio is 11.31. In terms of profitability, REGN's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, REGN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CPRX's competition here
REGN vs DYN Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, DYN has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $654.27, while DYN trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas DYN's P/E ratio is -7.16. In terms of profitability, REGN's ROE is +0.14%, compared to DYN's ROE of -0.58%. Regarding short-term risk, REGN is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check DYN's competition here
REGN vs RYZB Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $654.27, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas RYZB's P/E ratio is -57.86. In terms of profitability, REGN's ROE is +0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, REGN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check RYZB's competition here
REGN vs CBAY Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $654.27, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas CBAY's P/E ratio is -32.81. In terms of profitability, REGN's ROE is +0.14%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, REGN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for REGN.Check CBAY's competition here
REGN vs TNGX Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $654.27, while TNGX trades at $29.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas TNGX's P/E ratio is -35.49. In terms of profitability, REGN's ROE is +0.14%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, REGN is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check TNGX's competition here
REGN vs BEAM Comparison July 2026
REGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 67.4B. In comparison, BEAM has a market cap of 3.6B. Regarding current trading prices, REGN is priced at $654.27, while BEAM trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 14.34, whereas BEAM's P/E ratio is -11.19. In terms of profitability, REGN's ROE is +0.14%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, REGN is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for REGN.Check BEAM's competition here